Inovio Pharmaceuticals Inc vs ProShares Ultra Semiconductors — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while ProShares Ultra Semiconductors trades at $87.85. The key difference: ProShares Ultra Semiconductors is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | USD | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $2.87 | $113.53 |
52-Week Low | $1.05 | $39.58 |
Enterprise Value | $60.28M | — |
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
USD trades at $83.24, up 1.19% with bearish technical signals from moving averages. Key support lies at $80 with resistance at $85. The company announced a $0.14 dividend for H1-2026, payable June 30, 2026. Recent news highlights include coverage of semiconductor sector volatility and earnings from various firms, though specific financials for USD are not detailed in the provided data.
The outlook remains cautious due to bearish technical indicators and limited fundamental data. Investment opportunity hinges on upcoming financial disclosures and sector performance, while risks include market volatility and reliance on broader economic conditions affecting semiconductor and related industries.
Trailing returns across standard periods
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →